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We congratulate the researchers on their impressive study. There is a lesson to learn from Gilbody et al.,
except it is not about effectiveness, it is about engagement and adherence.
Gilbody et al. (2015) reported “no additional improvement in depression compared with usual GP care at four
months” for participants who were offered computer-delivered CBT (cCBT).(1) Offered is the operative word
because Gilbody et al. found that participants used only 1-2 sessions of the programs. This level of adherence
makes it impossible to conclude anything about effectiveness. This shows poor adherence. This is akin to
saying that a pharmaceutical drug that reduces depression doesn’t work when the real issue is that people
don’t want to take it because of side effects or poor explanation from their doctor.
Analyses addressing predictors of adherence are missing from this paper. The adjunct cCBT programmes
may be ineffective or participants may have received sufficient usual care to reduce cCBT’s relevance. To
properly test this requires a dismantling trial in which all participants received the same dose of treatment.
Otherwise, this turns into testing a phantom.
The overlap between experimental and control groups obfuscates outcome.
This was a pragmatic trial, meaning that there were no restrictions on access to other treatment. This is an
important test to examine real-world usage patterns of various treatment modalities. It is not appropriate for
determining the efficacy of a single intervention. The authors reported that 19% of the GP care group had also
actively used cCBT. When a substantial proportion of participants in the control group receive a similar
intervention to those in the active experimental groups, it is difficult to make a conclusion about the superiority
of one versus the others. Moreover, between 77% (MoodGYM) and 84% (GP treatment only group) received
also pharmacological treatment for depression. Meta-analytic evidence indicates that the additional effect of
(face-to-face) psychotherapy to pharmacological treatment only is small.(2) If a substantial proportion of all
groups in addition to the pharmacological treatment also receive psychological treatment for depression in
secondary care (17% in the MoodGYM group, to 28% in the GP group) it is no wonder that the authors can´t
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find large differences between the groups.
The general design of the trial is properly chosen under the hypothesis that cCBT was more effective than GP
Care. Nevertheless, the conclusion that cCBT is not superior to GP care cannot be drawn based on this trial
design. The lack of significance of a statistical test for superiority does not prove equivalence (or
non-inferiority). The fact that both arms of adjunct treatment do not show superiority over GP care supports
the impression of a lack of assay sensitivity, meaning, the ability to distinguish effective treatments from less
effective or ineffective treatments.(3) The International Conference on Harmonization (ICH) lists a number of
factors that can reduce assay sensitivity.(4) These include poor compliance with the study
medication/intervention as observed in the current trial.
Therefore, the question of whether cCBT is really not superior to GP care in a pragmatic setting remains
unanswered. This question could only be answered in a prospective confirmatory non-inferiority or
equivalence trial. While hypothetically, it would be possible to change the presented analysis from superiority
to a non-inferiority analysis there are several requirements for this decision (e.g., in the trial protocol
predefined or otherwise justified non-inferiority margins which are not met in the current trial.(5)
For the presented non-inferiority comparison between Beating the Blues and MoodGYM the analysis should
be repeated in the per-protocol collective to increase confidence in the results.(6)
The investigated interventions do not represent the standard for cCBT programmes.
There are numerous meta-analyses showing that guided self-help cCBT programmes have superior
adherence and outcomes to self-guided programmes. MoodGYM is used as an “open access” and unguided
intervention, which is not as effective as guided self-help. The adherence and engagement found in the
Gilbody et al. study is worse than what has been reported in meta-analyses for other self-guided depression
programmes which show completion rates of approximately 80%.(7)
The nature of the “support” provided in REEACT would not likely meet current standards for guidance in
cCBT. Evidence suggests that specific guidance or “support” behaviors predict better outcomes: individualized
feedback with task reinforcement, task prompting, and empathetic communication.(8) REEACT described
only task prompting: reminders to complete sessions. While others have shown that online CBT with guidance
from a technician can be equally effective to the same intervention provided by clinicians (e.g., Titov et al.),
the quality of guidance provided by the technicians in REEACT is a key open question.(9)
How these programmes are implemented and introduced to participants is critical. The way a treatment is
presented has substantial effects on adherence and, relatedly, treatment outcome expectancy.(10) Context
matters probably most in such treatments, as does usability. Improved design elements such as mobile-first
technology and personalisation can likely further boost engagement.
Zooming out: Using stepped care to reduce mental health care disparities
The objective of cCBT developers and researchers is not to eliminate in person care. It is to create more
options within the mental health care ecosystem to improve access to effective care. The fact remains that
while usual care is effective– the wait times and cost of accessing specialist or GP services are often
prohibitive. Digital mental health technology offers a promising path to bridge this gap, assisting individuals
whose needs can be effectively met with a lower intensity approach. Moreover, only a limited percentage of
those in need of mental health treatment actually utilise it. Research indicates that this is not only a problem of
evidence-based treatment availability, but also of poor utilization due to other barriers, such as stigma.(11)
Digital programmes offer a low-threshold and highly acceptable (to many) way of investing in one’s own
emotional wellbeing which for many, might be the only care they can receive.
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